Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO
European Journal of Neurology · 2025-08 · 32 (8)
DOI: 10.1111/ene.70231 ↗At a glance
Randomisierte kontrollierte Studie in European Journal of Neurology, published online on 2025-08-04. Written by Henry J Kaminski and 12 co-authors. Institution: Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, District of Columbia, USA. Major MEDLINE topics: Myasthenia Gravis, Patient Reported Outcome Measures, Antibodies, Monoclonal, Humanized. Cited 3 times so far (Crossref); 33 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: UCB.
Abstract (original language)
Background
In the Phase 3 MycarinG study (NCT03971422), rozanolixizumab improved myasthenia gravis (MG)‐specific outcomes versus placebo in patients with generalised MG, including those measured by the five independent MG Symptoms patient‐reported outcome (PRO) scales: Muscle Weakness Fatigability (MWF), Physical Fatigue (PF) and Bulbar Muscle Weakness (BMW) as secondary endpoints and Ocular Muscle Weakness and Respiratory Muscle Weakness (exploratory endpoints). This research aimed to provide further insights into these improvements.
Methods
Post hoc analyses evaluated correlation (Pearson coefficient) between MG Symptoms PRO and subdomain scores of MG Activities of Daily Living (MG‐ADL) and Quantitative MG (QMG) at baseline. Proportions of responders reaching clinically meaningful thresholds and analyses at the item level (observed mean change and Rasch modelling of predicted change from baseline) are reported for MWF, PF, and BMW with rozanolixizumab versus placebo at Day 43.
Results
Correlation coefficients between MG Symptoms PRO and MG‐ADL were strong (≥ 0.7) for ocular and bulbar scores and moderate (0.5 to < 0.7) for other scores. Correlations with clinician‐assessed QMG scores were generally weak (< 0.5). For MWF, PF, and BMW, greater proportions of responders were observed with rozanolixizumab 7 mg/kg (46.9%, 31.3% and 26.6%, respectively) or 10 mg/kg (56.5%, 48.4% and 32.3%) versus placebo (28.1%, 26.6% and 10.9%). Item‐level analyses demonstrated rozanolixizumab benefit at a symptom‐specific level.
Discussion
MG Symptoms PRO scales correlate well with concepts in MG‐ADL while assessing additional concepts, such as PF and MWF. Results from the MG Symptoms PRO in MycarinG reflected improvements from baseline in patient‐relevant symptoms, including fatigue, with rozanolixizumab.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neurology & Rehabilitation Medicine, George Washington University, Washington, District of Columbia, USA.
- Neuroimmunology and Muscle Pathology Unit, Multiple Sclerosis Center, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Neurologico Carlo Besta, Milan, Italy.
- MDA ALS & Neuromuscular Center, Department of Neurology, University of California Irvine, Orange, California, USA.
- Neurology Department, Indiana University School of Medicine, Indiana University Health, Indianapolis, Indiana, USA.
- Université Côte d'Azur, Peripheral Nervous System & Muscle Department, Pasteur 2 Hospital, Centre Hospitalier Universitaire de Nice, Nice, France.
- Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan.
ORCID profiles: Carlo Antozzi, Ali A Habib, Vera Bril
Funding
- UCB
Cite
APA
Kaminski, H. J., Antozzi, C., Habib, A. A., Pascuzzi, R. M., Sacconi, S., Utsugisawa, K., Vissing, J., Regnault, A., Hareendran, A., Grimson, F., Tarancón, T., Bril, V., & MycarinG study investigators (2025). Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. European Journal of Neurology, 32(8). https://doi.org/10.1111/ene.70231
Vancouver
Kaminski HJ, Antozzi C, Habib AA, Pascuzzi RM, Sacconi S, Utsugisawa K, et al. Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO. European Journal of Neurology. 2025;32(8). doi:10.1111/ene.70231
BibTeX
@article{Kaminski2025,
author = {Kaminski, Henry J and Antozzi, Carlo and Habib, Ali A and Pascuzzi, Robert M and Sacconi, Sabrina and Utsugisawa, Kimiaki and Vissing, John and Regnault, Antoine and Hareendran, Asha and Grimson, Fiona and Tarancón, Thaïs and Bril, Vera and MycarinG study investigators, MycarinG study investigators},
title = {Improvement in Patient‐Reported Symptoms of Generalised Myasthenia Gravis With Rozanolixizumab in the Randomised Phase 3 MycarinG Study Using the MG Symptoms PRO},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {8},
doi = {10.1111/ene.70231}
}
EUVIMED